Gotlib Phyllis sold $87K of AMWL

Gotlib Phyllis (President, International) sold 6,677 shares of American Well Corp (AMWL) at $13.00 on 2026-10-01.

Original reporting
SEC EDGAR · Gotlib Phyllis
Published Oct 5, 2026, 9:32 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 5, 2026, 9:32 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$AMWL
Bearish
medium confidence
Mentioned
$AMWL
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AMWLBearishLow
01

Why it matters

The disclosed sale adds a data point for investors monitoring insider activity, but the modest amount limits its market impact.

02

Market read

Provides fresh insider transaction data; modest sell may cause slight short-term price pressure.

03

What to watch

The insider retains a large position (over 140k shares), indicating continued confidence.

Relevance 3/10Novelty 3/10Timing: after-hours filing on Oct 5

Background

Form 4 filings disclose insider transactions; this filing reports a sale by the President of American Well Corp.

Company-level read

Ticker impact

$AMWLBearishMedium confidence
Context

President Gotlib Phyllis sold 6,677 shares for $86,801, reducing her stake to 142,504 shares.

Expected impact

likely slight downward pressure as the market prices the insider sell.

Evidence & confidence

A C-level insider sold nearly $87k of stock; while the amount is modest, such sales can signal concerns and prompt short-term price dip.

Market effects

Minimal impact on the broader telehealth sector.

Limited to U.S. investors tracking AMWL.

None

Counterpoint

The sale size is too small to affect price; investors may ignore it.

Key entities

  • American Well Corp

    U.S.-listed telehealth provider (ticker AMWL).

  • Gotlib Phyllis

    President, International of AMWL.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$AMWLMed

American Well Corp (AMWL) Q3 2026 Earnings Call Highlights: Revenue Beat, Raised Guidance

American Well Corp (AMWL) reported Q3 2026 revenue of $49M, down 12.9% YoY. Subscription revenue fell 22.5% due to churn. Platform visits dropped 30.5% YoY. The VA letter of intent is non-binding, and the DHA contract conversion is pending. CEO Dr. Ido Schoenberg expressed optimism about negotiations and potential growth opportunities. The company expects Q4 adjusted EBITDA breakeven and raised guidance.

$AMWLMedAI 8/10

What American Well (AMWL) Said on Its Q3 Earnings Call

Amwell (AMWL) reported Q3 earnings with virtual primary care visits up 41% YoY, but total platform visits down 30.5%. Gross profit was $26M with a 53% margin. Q4 revenue is forecasted at $48M-$50M, with adjusted EBITDA expected to break even or turn positive. The company raised its full-year 2026 outlook, now expecting revenue of $204M-$206M and a reduced adjusted EBITDA loss. Amwell also discussed potential government contracts, including a nonbinding letter of intent from the VA.

$AMWLHigh

American Well Corp (AMWL): AMWELL® ANNOUNCES RESULTS FOR THE third QUARTER 2026

American Well Corp (AMWL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 AMWELL® ANNOUNCES RESULTS FOR THE third QUARTER 2026 BOSTON, November 3 , 2026 –Amwell ® (NYSE: AMWL), a leading provider of a comprehensive SaaS-based technology-enabled healthcare platform, today announced financial results for the third quarter ended September 30,

$AMWLMedAI 8/10

American Well (AMWL) Q2 2026 Earnings Call Transcript

American Well (AMWL) reported Q2 2026 revenue of $52 million, down 26.6% year over year, with subscription revenue of $25.7 million and AMG revenue of $24.4 million. Adjusted EBITDA loss was $1.15 million and net loss was $9.6 million. Full-year guidance was narrowed to $200-$205 million revenue and improved adjusted EBITDA loss to $9-$7 million. The Defense Health Agency issued an intent to award a sole-source contract.